Detalhe da pesquisa
1.
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.
Br J Haematol
; 159(2): 154-63, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22881386
2.
Lenalidomide-induced tumour flare reaction in mantle cell lymphoma.
Br J Haematol
; 151(4): 410-2, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20880113
3.
Autoimmune haemolytic anaemia associated with mantle cell lymphoma.
Int J Hematol
; 91(2): 322-5, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20063131
4.
Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study.
Leuk Lymphoma
; 50(2): 211-5, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19197729
5.
Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab.
Leuk Lymphoma
; 50(3): 463-5, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19197732
6.
The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized phase II trial.
Leuk Lymphoma
; 50(10): 1709-11, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19757310
7.
Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma.
J Clin Oncol
; 27(32): e189-90; author reply e191, 2009 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19805667